Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 507

1.

The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment.

Bakhoum SF, Cantley LC.

Cell. 2018 Sep 6;174(6):1347-1360. doi: 10.1016/j.cell.2018.08.027. Review.

PMID:
30193109
2.

Publisher Correction: Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.

Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, Amadiume SC, Goncalves MD, Hodakoski C, Lundquist MR, Bareja R, Ma Y, Harris EM, Sboner A, Beltran H, Rubin MA, Mukherjee S, Cantley LC.

Nature. 2018 Aug 29. doi: 10.1038/s41586-018-0506-3. [Epub ahead of print]

PMID:
30158705
3.

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.

Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, Amadiume SC, Goncalves MD, Hodakoski C, Lundquist MR, Bareja R, Ma Y, Harris EM, Sboner A, Beltran H, Rubin MA, Mukherjee S, Cantley LC.

Nature. 2018 Aug;560(7719):499-503. doi: 10.1038/s41586-018-0343-4. Epub 2018 Jul 4. Erratum in: Nature. 2018 Aug 29;:.

PMID:
30051890
4.

A Glycolysis Outsider Steps into the Cancer Spotlight.

Goncalves MD, Cantley LC.

Cell Metab. 2018 Jul 3;28(1):3-4. doi: 10.1016/j.cmet.2018.06.017.

PMID:
29972796
5.

Cancer metabolism gets physical.

DelNero P, Hopkins BD, Cantley LC, Fischbach C.

Sci Transl Med. 2018 May 23;10(442). pii: eaaq1011. doi: 10.1126/scitranslmed.aaq1011. Review.

6.

Diverting Glycolysis to Combat Oxidative Stress.

Mullarky E, Cantley LC.

In: Nakao K, Minato N, Uemoto S, editors. Innovative Medicine: Basic Research and Development [Internet]. Tokyo: Springer; 2015.

7.

Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma.

Anglin J, Zavareh RB, Sander PN, Haldar D, Mullarky E, Cantley LC, Kimmelman AC, Lyssiotis CA, Lairson LL.

Bioorg Med Chem Lett. 2018 Sep 1;28(16):2675-2678. doi: 10.1016/j.bmcl.2018.04.061. Epub 2018 Apr 27.

PMID:
29731362
8.

Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy.

Lundquist MR, Goncalves MD, Loughran RM, Possik E, Vijayaraghavan T, Yang A, Pauli C, Ravi A, Verma A, Yang Z, Johnson JL, Wong JCY, Ma Y, Hwang KS, Weinkove D, Divecha N, Asara JM, Elemento O, Rubin MA, Kimmelman AC, Pause A, Cantley LC, Emerling BM.

Mol Cell. 2018 May 3;70(3):531-544.e9. doi: 10.1016/j.molcel.2018.03.037.

PMID:
29727621
9.

Chromosomal instability drives metastasis through a cytosolic DNA response.

Bakhoum SF, Ngo B, Laughney AM, Cavallo JA, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK, Duran M, Pauli C, Shaw C, Chadalavada K, Rajasekhar VK, Genovese G, Venkatesan S, Birkbak NJ, McGranahan N, Lundquist M, LaPlant Q, Healey JH, Elemento O, Chung CH, Lee NY, Imielenski M, Nanjangud G, Pe'er D, Cleveland DW, Powell SN, Lammerding J, Swanton C, Cantley LC.

Nature. 2018 Jan 25;553(7689):467-472. doi: 10.1038/nature25432. Epub 2018 Jan 17.

10.

Fenofibrate prevents skeletal muscle loss in mice with lung cancer.

Goncalves MD, Hwang SK, Pauli C, Murphy CJ, Cheng Z, Hopkins BD, Wu D, Loughran RM, Emerling BM, Zhang G, Fearon DT, Cantley LC.

Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E743-E752. doi: 10.1073/pnas.1714703115. Epub 2018 Jan 8. Erratum in: Proc Natl Acad Sci U S A. 2018 Feb 20;:.

11.

PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors.

Croessmann S, Sheehan JH, Lee KM, Sliwoski G, He J, Nagy R, Riddle D, Mayer IA, Balko JM, Lanman R, Miller VA, Cantley LC, Meiler J, Arteaga CL.

Clin Cancer Res. 2018 Mar 15;24(6):1426-1435. doi: 10.1158/1078-0432.CCR-17-2141. Epub 2017 Dec 28.

PMID:
29284706
12.

Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.

Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC.

Cancer Discov. 2018 Mar;8(3):354-369. doi: 10.1158/2159-8290.CD-17-0679. Epub 2017 Dec 4. Erratum in: Cancer Discov. 2018 Aug;8(8):1044.

PMID:
29203461
13.

Post-transcriptional Regulation of De Novo Lipogenesis by mTORC1-S6K1-SRPK2 Signaling.

Lee G, Zheng Y, Cho S, Jang C, England C, Dempsey JM, Yu Y, Liu X, He L, Cavaliere PM, Chavez A, Zhang E, Isik M, Couvillon A, Dephoure NE, Blackwell TK, Yu JJ, Rabinowitz JD, Cantley LC, Blenis J.

Cell. 2017 Dec 14;171(7):1545-1558.e18. doi: 10.1016/j.cell.2017.10.037. Epub 2017 Nov 16.

PMID:
29153836
14.

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu F, Matés JM, Asara JM, Kim JW, Hankins JH, Weekes C, Hollingsworth MA, Serkova NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK.

Cancer Cell. 2017 Sep 11;32(3):392. doi: 10.1016/j.ccell.2017.08.008. No abstract available.

15.

The PI3K Pathway in Human Disease.

Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT.

Cell. 2017 Aug 10;170(4):605-635. doi: 10.1016/j.cell.2017.07.029. Review.

16.

Proteomic and Metabolomic Characterization of a Mammalian Cellular Transition from Quiescence to Proliferation.

Lee HJ, Jedrychowski MP, Vinayagam A, Wu N, Shyh-Chang N, Hu Y, Min-Wen C, Moore JK, Asara JM, Lyssiotis CA, Perrimon N, Gygi SP, Cantley LC, Kirschner MW.

Cell Rep. 2017 Jul 18;20(3):721-736. doi: 10.1016/j.celrep.2017.06.074.

17.

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu F, Matés JM, Asara JM, Kim JW, Hankins JH, Weekes C, Hollingsworth MA, Serkova NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK.

Cancer Cell. 2017 Jul 10;32(1):71-87.e7. doi: 10.1016/j.ccell.2017.06.004. Erratum in: Cancer Cell. 2017 Sep 11;32(3):392.

18.

PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.

Thorpe LM, Spangle JM, Ohlson CE, Cheng H, Roberts TM, Cantley LC, Zhao JJ.

Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7095-7100. doi: 10.1073/pnas.1704706114. Epub 2017 Jun 19.

19.

Phosphorylation of TXNIP by AKT Mediates Acute Influx of Glucose in Response to Insulin.

Waldhart AN, Dykstra H, Peck AS, Boguslawski EA, Madaj ZB, Wen J, Veldkamp K, Hollowell M, Zheng B, Cantley LC, McGraw TE, Wu N.

Cell Rep. 2017 Jun 6;19(10):2005-2013. doi: 10.1016/j.celrep.2017.05.041.

20.

Membrane Lipids Speak to Histones.

Zheng Y, Cantley LC.

Mol Cell. 2017 Apr 20;66(2):163-164. doi: 10.1016/j.molcel.2017.04.001.

21.

Positive and negative roles of p85α and p85β regulatory subunits of phosphoinositide 3-kinase in insulin signaling.

Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, Kahn CR.

J Biol Chem. 2017 Mar 31;292(13):5608. doi: 10.1074/jbc.A117.305602. No abstract available.

22.

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, Rao R, Mosquera JM, Robinson B, Faltas BM, Emerling BE, Gadi VK, Bernard B, Elemento O, Beltran H, Demichelis F, Kemp CJ, Grandori C, Cantley LC, Rubin MA.

Cancer Discov. 2017 May;7(5):462-477. doi: 10.1158/2159-8290.CD-16-1154. Epub 2017 Mar 22.

23.

PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation.

Gupta A, Anjomani-Virmouni S, Koundouros N, Dimitriadi M, Choo-Wing R, Valle A, Zheng Y, Chiu YH, Agnihotri S, Zadeh G, Asara JM, Anastasiou D, Arends MJ, Cantley LC, Poulogiannis G.

Mol Cell. 2017 Mar 16;65(6):999-1013.e7. doi: 10.1016/j.molcel.2017.02.019.

24.

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.

Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC, Elemento O, Novak J, Thornley TB, Asara JM, Montaser L, Timmons JJ, Morgan TM, Wang Y, Levantini E, Clohessy JG, Kelly K, Pandolfi PP, Rosenblatt JM, Avigan DE, Ye H, Karp JM, Signoretti S, Balk SP, Cantley LC.

Cancer Discov. 2017 Jul;7(7):750-765. doi: 10.1158/2159-8290.CD-16-0778. Epub 2017 Mar 8.

25.

PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition.

Mathur D, Stratikopoulos E, Ozturk S, Steinbach N, Pegno S, Schoenfeld S, Yong R, Murty VV, Asara JM, Cantley LC, Parsons R.

Cancer Discov. 2017 Apr;7(4):380-390. doi: 10.1158/2159-8290.CD-16-0612. Epub 2017 Mar 2.

26.

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.

de Oliveira Taveira M, Nabavi S, Wang Y, Tonellato P, Esteva FJ, Cantley LC, Wulf GM.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1255-1262. doi: 10.1007/s00432-017-2358-x. Epub 2017 Feb 28.

27.

Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma.

Trousil S, Chen S, Mu C, Shaw FM, Yao Z, Ran Y, Shakuntala T, Merghoub T, Manstein D, Rosen N, Cantley LC, Zippin JH, Zheng B.

J Invest Dermatol. 2017 May;137(5):1135-1143. doi: 10.1016/j.jid.2017.01.013. Epub 2017 Jan 28.

28.

Death-associated protein kinase 1 phosphorylates NDRG2 and induces neuronal cell death.

You MH, Kim BM, Chen CH, Begley MJ, Cantley LC, Lee TH.

Cell Death Differ. 2017 Feb;24(2):238-250. doi: 10.1038/cdd.2016.114. Epub 2016 Nov 4.

29.

α-Ketothioamide Derivatives: A Promising Tool to Interrogate Phosphoglycerate Dehydrogenase (PHGDH).

Ravez S, Corbet C, Spillier Q, Dutu A, Robin AD, Mullarky E, Cantley LC, Feron O, Frédérick R.

J Med Chem. 2017 Feb 23;60(4):1591-1597. doi: 10.1021/acs.jmedchem.6b01166. Epub 2017 Jan 27.

30.

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.

Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E.

Ann Oncol. 2017 Mar 1;28(3):512-518. doi: 10.1093/annonc/mdw672.

31.

Obesity and Cancer Mechanisms: Cancer Metabolism.

Hopkins BD, Goncalves MD, Cantley LC.

J Clin Oncol. 2016 Dec 10;34(35):4277-4283. Epub 2016 Nov 7. Review.

32.

Erratum: Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion.

Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, Kremer D, Hwang RF, Witkiewicz AK, Ying H, Asara JM, Evans RM, Cantley LC, Lyssiotis CA, Kimmelman AC.

Nature. 2016 Dec 1;540(7631):150. doi: 10.1038/nature19851. Epub 2016 Oct 5. No abstract available.

PMID:
27706144
33.

A novel small-molecule inhibitor of 3-phosphoglycerate dehydrogenase.

Mullarky E, Lairson LL, Cantley LC, Lyssiotis CA.

Mol Cell Oncol. 2016 Mar 30;3(4):e1164280. doi: 10.1080/23723556.2016.1164280. eCollection 2016 Jul.

34.

Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer.

Lien EC, Lyssiotis CA, Cantley LC.

Recent Results Cancer Res. 2016;207:39-72. doi: 10.1007/978-3-319-42118-6_3. Review.

PMID:
27557534
35.

Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival.

Wang Y, Begley M, Li Q, Huang HT, Lako A, Eck MJ, Gray NS, Mitchison TJ, Cantley LC, Zhao JJ.

Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):9810-5. doi: 10.1073/pnas.1606862113. Epub 2016 Aug 15.

36.

Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion.

Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, Kremer D, Hwang RF, Witkiewicz AK, Ying H, Asara JM, Evans RM, Cantley LC, Lyssiotis CA, Kimmelman AC.

Nature. 2016 Aug 25;536(7617):479-83. doi: 10.1038/nature19084. Epub 2016 Aug 10. Erratum in: Nature. 2016 Dec 1;540(7631):150.

37.

Seeking out the sweet spot in cancer therapeutics: an interview with Lewis Cantley.

Cantley LC.

Dis Model Mech. 2016 Sep 1;9(9):911-6. doi: 10.1242/dmm.026856. Epub 2016 Aug 4.

38.

Prioritization schema for immunotherapy clinical trials in glioblastoma.

Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB.

Oncoimmunology. 2016 Feb 18;5(6):e1145332. doi: 10.1080/2162402X.2016.1145332. eCollection 2016 Jun. Review.

39.

Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.

Juvekar A, Hu H, Yadegarynia S, Lyssiotis CA, Ullas S, Lien EC, Bellinger G, Son J, Hok RC, Seth P, Daly MB, Kim B, Scully R, Asara JM, Cantley LC, Wulf GM.

Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4338-47. doi: 10.1073/pnas.1522223113. Epub 2016 Jul 8.

40.

Deletion of the gene Pip4k2c, a novel phosphatidylinositol kinase, results in hyperactivation of the immune system.

Shim H, Wu C, Ramsamooj S, Bosch KN, Chen Z, Emerling BM, Yun J, Liu H, Choo-Wing R, Yang Z, Wulf GM, Kuchroo VK, Cantley LC.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7596-601. doi: 10.1073/pnas.1600934113. Epub 2016 Jun 16.

41.

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.

Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL.

Clin Cancer Res. 2017 Jan 1;23(1):26-34. doi: 10.1158/1078-0432.CCR-16-0134. Epub 2016 Apr 28.

42.

Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer.

Lien EC, Lyssiotis CA, Juvekar A, Hu H, Asara JM, Cantley LC, Toker A.

Nat Cell Biol. 2016 May;18(5):572-8. doi: 10.1038/ncb3341. Epub 2016 Apr 18.

43.

Erratum: NRF2 regulates serine biosynthesis in non-small cell lung cancer.

DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, Tang H, Xie Y, Asara JM, Huffman KE, Wistuba II, Minna JD, DeBerardinis RJ, Cantley LC.

Nat Genet. 2016 Apr;48(4):473. doi: 10.1038/ng0329-473a. No abstract available.

PMID:
27023779
44.

A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2.

Breitkopf SB, Yang X, Begley MJ, Kulkarni M, Chiu YH, Turke AB, Lauriol J, Yuan M, Qi J, Engelman JA, Hong P, Kontaridis MI, Cantley LC, Perrimon N, Asara JM.

Sci Rep. 2016 Feb 3;6:20471. doi: 10.1038/srep20471.

45.

Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers.

Mullarky E, Lucki NC, Beheshti Zavareh R, Anglin JL, Gomes AP, Nicolay BN, Wong JC, Christen S, Takahashi H, Singh PK, Blenis J, Warren JD, Fendt SM, Asara JM, DeNicola GM, Lyssiotis CA, Lairson LL, Cantley LC.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1778-83. doi: 10.1073/pnas.1521548113. Epub 2016 Feb 1. Erratum in: Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):E1585.

46.

Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton.

Hu H, Juvekar A, Lyssiotis CA, Lien EC, Albeck JG, Oh D, Varma G, Hung YP, Ullas S, Lauring J, Seth P, Lundquist MR, Tolan DR, Grant AK, Needleman DJ, Asara JM, Cantley LC, Wulf GM.

Cell. 2016 Jan 28;164(3):433-46. doi: 10.1016/j.cell.2015.12.042.

47.

Cancer's Fuel Choice: New Flavors for a Picky Eater.

DeNicola GM, Cantley LC.

Mol Cell. 2015 Nov 19;60(4):514-23. doi: 10.1016/j.molcel.2015.10.018. Review.

48.

EGF-receptor specificity for phosphotyrosine-primed substrates provides signal integration with Src.

Begley MJ, Yun CH, Gewinner CA, Asara JM, Johnson JL, Coyle AJ, Eck MJ, Apostolou I, Cantley LC.

Nat Struct Mol Biol. 2015 Dec;22(12):983-90. doi: 10.1038/nsmb.3117. Epub 2015 Nov 9.

49.

Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.

Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K, Roper J, Chio II, Giannopoulou EG, Rago C, Muley A, Asara JM, Paik J, Elemento O, Chen Z, Pappin DJ, Dow LE, Papadopoulos N, Gross SS, Cantley LC.

Science. 2015 Dec 11;350(6266):1391-6. doi: 10.1126/science.aaa5004. Epub 2015 Nov 5.

50.

NRF2 regulates serine biosynthesis in non-small cell lung cancer.

DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, Tang H, Xie Y, Asara JM, Huffman KE, Wistuba II, Minna JD, DeBerardinis RJ, Cantley LC.

Nat Genet. 2015 Dec;47(12):1475-81. doi: 10.1038/ng.3421. Epub 2015 Oct 19. Erratum in: Nat Genet. 2016 Apr;48(4):473.

Supplemental Content

Loading ...
Support Center